Table 2. Baseline characteristics of study participants, stratified by both *PNPLA3* rs738409 polymorphism and significant liver fibrosis (SF).

	CC			GC			GG		
	No SF (n=122)	SF (n= 22)	P value	No SF (n=203)	SF (n= 49)	P value	No SF (n=96)	SF (n=31)	P value
Demographics									
Age (years)	43.6 ± 12.4	45.6 ± 11.2	0.484	41.10 ± 11.3	43.4 ± 15.1	0.232	41.6 ± 10.1	45.8 ± 14.9	0.076
Men, n (%)	91 (74.6)	13 (59.1)	0.135	161 (79.3%)	30 (61.2%)	0.008	68 (70.8%)	18 (58.1%)	0.186
Metabolic risk factors									
Body mass index (kg/m^2)	26.9 ± 4.1	27.9 ± 6.5	0.341	26.6 ± 3.1	28.3 ± 4.5	0.002	26.2 ± 2.9	28.4 ± 3.3	<0.001
Overweight/obesity, n (%)	85 (69.7)	15 (68.2)	0.889	139 (68.5)	35 (71.4)	0.688	59 (61.5)	27 (87.1)	0.008
Visceral fat area (cm^2)	103.3 ± 26.2	107.0 ± 19.3	0.534	99.4 ± 24.3	114.7 ± 27.7	<0.001	95.0 ± 23.7	125.0 ± 26.2	<0.001
Type 2 diabetes, n (%)	35 (28.7)	6 (27.3)	0.892	46 (22.7%)	16 (32.7%)	0.145	19 (19.8%)	13 (41.9%)	0.014
Hypertension, n (%)	34 (27.9)	3 (13.6)	0.160	41 (20.2%)	13 (26.5%)	0.332	22 (22.9%)	13 (41.9%)	0.039
Laboratory parameters									
AST (U/L)	31.0 (23.2-43.0)	52.0 (35.0-75.8)	<0.001	32.0 (24.0-49.0)	54.0 (32.0-76.0)	<0.001	34.0 (26.0-53.8)	50.0 (29.0-65.0)	0.040
ALT (U/L)	39.0 (27.0-67.5)	74.5 (51.2-98.5)	<0.001	48.0 (28.0-86.5)	72.0 (43.0-129.0)	0.006	53.5 (30.8-87.2)	72.0 (32.5-120.0)	0.185
GGT (U/L)	50.0 (29.2-78.0)	68.5 (37.2-118.2)	0.058	53.0 (32.5-83.0)	60.0 (42.0-99.0)	0.074	47.5 (30.8-74.5)	66.0 (32.0-116.0)	0.126
Total bilirubin (μmol/L)	12.0 (10.0-15.0)	14.0 (9.2-17.0)	0.566	13.0 (10.0-16.0)	12.0 (9.0-15.0)	0.135	12.0 (10.0-16.0)	14.0 (11.0-18.0)	0.343
Albumin (g/L)	46.0 ± 3.6	47.0 ± 2.8	0.214	46.1 ± 3.7	45.3 ± 4.1	0.185	45.9 ± 4.8	45.0 ± 5.5	0.383
Glucose (mmol/L)	5.5 (5.0-6.6)	5.3 (4.8-6.0)	0.338	5.2 (4.8-6.0)	5.6 (4.9-7.9)	0.012	5.2 (4.9-5.8)	5.7 (5.0-7.2)	0.042
Insulin (mIU/L)	15.4 (9.2-21.3)	13.9 (10.0-21.6)	0.987	13.0 (9.2-18.4)	21.4 (15.2-32.6)	<0.001	14.0 (9.8-19.7)	16.9 (10.1-23.2)	0.268
HOMA-IR score	3.7 (2.3-5.4)	3.4 (2.2-6.3)	0.769	3.2 (2.3-4.5)	5.3 (4.1-11.1)	<0.001	3.3 (2.2-5.0)	4.3 (2.9-7.4)	0.060
Total cholesterol (mmol/L)	5.1 ± 1.2	4.6 ± 1.4	0.057	5.1 ±1.0	5.4 ± 1.3	0.074	5.2 ± 1.2	5.4 ± 1.4	0.347
Triglycerides (mmol/L)	2.1 (1.5-3.2)	1.7 (1.2-2.4)	0.072	1.9 (1.4-2.9)	2.0 (1.3-2.8)	0.965	1.8 (1.4-2.4)	1.8 (1.4-2.5)	0.982
HDL-cholesterol (mmol/L)	1.0 ± 0.2	1.0 ± 0.2	0.495	1.0 ± 0.2	1.0 ± 0.3	0.675	1.0 ± 0.2	1.1 ± 0.3	0.517
LDL-cholesterol (mmol/L)	2.9 ± 0.9	2.6 ± 1.1	0.128	3.0 ± 0.8	3.2 ± 1.1	0.245	3.1 ± 0.9	3.2 ± 1.1	0.530

Liver histology, n (%)

Steatosis grade			0.003			<0.001			0.021
1	76 (62.3)	7 (31.8)		87 (42.9)	14 (28.6)		34 (35.4)	4 (12.9)	
2	38 (31.1)	9 (40.9)		83 (40.9)	14 (28.6)		37 (38.5)	12 (38.7)	
3	8 (6.6)	6 (27.3)		33 (16.3)	21 (42.9)		25 (26.0)	15 (48.4)	
Hepatocyte ballooning			0.044			0.002			<0.001
0	21 (17.2)	1 (4.5)		34 (16.7)	4 (8.2)		17 (17.7)	1 (3.2)	
1	74 (60.7)	11 (50.0)		120 (59.1)	21 (42.9)		60 (62.5)	10 (32.3)	
2	27 (22.1)	10 (45.5)		49 (24.1)	24 (49.0)		19 (19.8)	20 (64.5)	
Lobular inflammation			0.002			<0.001			<0.001
0	24 (19.7)	1 (4.5)		24 (11.8)	5 (10.2)		10 (10.4)	0 (0.0)	
1	69 (56.6)	7 (31.8)		135 (66.5)	18 (36.7)		69 (71.9)	8 (25.8)	
2	28 (23.0)	13 (59.1)		43 (21.2)	25 (51.0)		16 (16.7)	20 (64.5)	
3	1 (0.8)	1 (4.5)		1 (0.5)	1 (2.0)		1 (1.0)	3 (9.7)	
Definite NASH	31 (25.4)	16 (72.7)	<0.001	65 (32.0)	30 (61.2)	<0.001	34 (35.4)	26 (83.9)	<0.001

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; HOMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; SF, significant fibrosis.